Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5278971 | 0.84 | SLC9A1 (0.35) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5280687 | 0.81 | SLC9A1 (0.33) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL31333003 | 0.81 | GRIA1 (0.37) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL20831303 | 0.78 | SLC9A1 (0.34) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5275132 | 0.78 | MAOB (0.32) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5277992 | 0.78 | GRIA1 (0.32) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5279736 | 0.78 | GRIA1 (0.38) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL20818442 | 0.77 | SLC9A1 (0.33) | SLC9A1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5280867 | 0.75 | — | — | |
| SCHEMBL5274100 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | SLC9A1 141/4885GRIA1 287/4885GRIA2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.